Search results for "chronic lymphocitic leukemia"

showing 2 items of 2 documents

Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaem…

2010

ChemokineChronic lymphocytic leukemiaT-LymphocytesCCL3CD38Settore MED/08 - Anatomia PatologicaCD49dMonocytesMacrophages; Tumor Cells Cultured; Leukemia Lymphocytic Chronic B-Cell; Humans; Monocytes; Chemokine CCL4; Chemokine CCL3; T-LymphocytesTumor Cells CulturedMedicineMacrophageHumansChronicChemokine CCL4Chemokine CCL3CulturedLeukemiabiologybusiness.industryMonocyteMacrophagesB-CellHematologyT lymphocytemedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphocyticTumor Cellsmedicine.anatomical_structureImmunologybiology.proteinbusinessSettore MED/15 - Malattie del SangueCCL3/CCL4 CD38CD49d chronic lymphocitic leukemia
researchProduct

Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials

2023

The treatment of chronic lymphocytic leukemia (CLL) currently relies on the use of chemo-immunotherapy, Bruton’s tyrosine kinase inhibitors, or BCL2 inhibitors alone or combined with an anti-CD20 monoclonal antibody. However, the availability of multiple choices for the first-line setting and a lack of direct head-to-head comparisons pose a challenge for treatment selection. To overcome these limitations, we performed a systematic review and a network meta-analysis on published randomized clinical trials performed in the first-line treatment setting of CLL. For each study, we retrieved data on progression-free survival (according to del17/P53 and IGHV status), overall response rate, complet…

network metanalysiBruton’s tyrosine kinase inhibitorschronic lymphocitic leukemiaCLL
researchProduct